Taking a statin is associated with a 46% increase in the risk of type 2 diabetes, a large follow-up study of men in Finland has found. The paper suggested that the effect was due to decreased insulin sensitivity and secretion. However, experts commenting on the findings have pointed out various flaws in the study and its presentation.
Taking a statin is associated with a 46% increase in the risk of type 2 diabetes, a large follow-up study of men in Finland has found. The paper suggested that the effect was due to decreased insulin sensitivity and secretion. However, experts commenting on the findings have pointed out various flaws in the study and its presentation.
The study followed up 8749 men aged 45 to 73 years for an average of 5.9 years. They were randomly selected from the population of Kuopio, eastern Finland, and none had diabetes at baseline. The results, reported in Diabetologia, showed that men taking statins (n=2142) had a 46% increased risk of developing type 2 diabetes (adjusted hazard ratio 1.46 (95% confidence interval 1.22 to 1.74)) over the follow-up period.
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Type 2 diabetes was diagnosed in 625 men on the basis of measurement of fasting plasma glucose, an oral glucose tolerance test or HbA 1c , or starting on glucose lowering treatment. More than a 10th (11.2%) of men taking statins but 5.8% of men not taking statins developed diabetes (P<0.001).
Analysing the effects of different statins showed that atorvastatin and simvastatin increased the risk of type 2 diabetes, but no increase was seen with other statins, although the numbers of men taking these statins were low. The results showed a greater increase in risk with high dose atorvastatin and simvastatin than with lower doses, reflecting the findings of previous studies.
The researchers measured insulin sensitivity and secretion in an effort to understand the mechanism underlying the increased diabetes risk with statins. They found that insulin sensitivity was 24% less in study participants taking statins and insulin secretion was 12% less than in men not taking statins (P<0.01). These reductions were dose dependent for both simvastatin and atorvastatin.
"The association of statin use with increased risk of developing diabetes is most likely directly related to statins decreasing both insulin sensitivity and secretion," said the researchers, led by Markku Laakso, of the University of Eastern Finland and Kuopio.
They concluded, "Statin therapy was associated with a 46% increased risk of type 2 diabetes after adjustment for confounding factors, suggesting a higher risk of diabetes in the general population than previously reported."
Commenting on the findings, Stephen Evans, professor of pharmacoepidemiology at the London School of Hygiene and Tropical Medicine, said, "This research adds little to our current knowledge. The study, slightly confusingly presented, compares people who were taking a statin at an initial measurement (when they were aged between 45 and 73) with those who were not taking any statin at that time. They were followed up for an average of nearly six years.
"The users of statins were generally at higher risk of heart disease and differed in a number of ways, probably including several ways that were not measured (no direct dietary measurements are reported). As expected, those who took a statin had a slightly increased risk of increasing their blood sugar. The paper does not properly discuss the absolute increase in the risk of having a diagnosis of diabetes. About one in 100 people per year of follow-up would have such a diagnosis made on the basis of blood tests. Taking a statin might increase that risk to about three people in 200 (1.5%).
"While the introduction mentions that statins are effective in treating and preventing cardiovascular disease in those with as well as in those without diabetes, the magnitude of this reduction is not set in context with the headline figure of a 46% increase in diabetes."
The University of Glasgow's David Preiss, senior clinical lecturer in metabolic medicine, and Naveed Sattar, professor of metabolic medicine, said, "This study broadly supports what we already know from clinical trials: that statin therapy leads to a modestly raised risk of developing diabetes." But they noted, "The fact that the study is observational, and not a clinical trial, is an important weakness, because we do not know why some patients in the study were on statins and the others were not, and this introduces bias." Preiss and Sattar added, "In our view the cardiovascular benefit of statins still heavily outweighs any diabetogenic risk in patients with moderate and elevated cardiovascular risk. However, clinicians should certainly be encouraging their patients to also make lifestyle improvements when starting a statin to reduce any diabetes risk."
